In Surprise Move, Pennsylvania Wants 340B Modifiers on Medicaid Managed Care Drugs

Pennsylvania
Pennsylvania 340B covered entities say they were blindsided by the state's disclosure last week that it wants drug claims billed to Medicaid managed care organizations to include a modifier showing if the prescription was filled with a 340B-purchased drug.

Pennsylvania health centers are upset about what they say was the state Medicaid office’s disclosure without warning last week that, starting July 1, it wants drug claims billed to Medicaid managed care organizations to include a modifier showing if the

Read More »

Daiichi-Sankyo Offering Refunds for 340B Overcharges on Two Drugs

Enhertu
Daiichi-Sankyo is offering refunds for 340B overcharges on its breast cancer drug Enhertu and cholesterol drug Welchol for Oral Suspension.

Drug manufacturer Daiichi-Sankyo is offering 340B covered entities refunds for overcharges on metastatic breast cancer treatment Enhertu during Q1 2020 and on cholesterol medication Welchol for Oral Suspension during Q1 2022 and Q4 2022.

The U.S. Health Resources and Services

Read More »

New 340B Transparency Bill to be Discussed Next Week in House Hearing, U.S. Senate Bills Introduced

Bucshon bill
Rep. Larry Bucshon (R-Ind.) has has written a bill to impose significant 340B program reporting requirements on disproportionate share hospitals and maybe other covered entities.

U.S. Rep. Larry Bucshon (R-Ind.), vice chair of the House Energy & Commerce health subcommittee, has written a bill to impose significant 340B program reporting requirements on disproportionate share hospitals and potentially other covered entities. Meanwhile, two bills have been

Read More »

HRSA Administrator Open to Congress’ Help Ensuring 340B Accountability and Transparency

Carole Johnson
HRSA Administrator Carole Johnson said during a House hearing yesterday she would welcome congressional help ensuring there is “accountability and transparency” in 340B.

U.S. Health Resources and Services Administration Administrator Carole Johnson said on Capitol Hill yesterday that HRSA would welcome congressional help ensuring there is “accountability and transparency” in the 340B program.

Johnson was answering questions from Rep. Morgan Griffith (R-Va.) during

Read More »

Closed Pennsylvania 340B Hospital Sues CVS Health Over 340B TPA Policy

Brandywine Hospital
A closed Pennsylvania hospital has filed a federal antitrust class action against CVS over its 340B contract pharmacy policies.

A Philadelphia-area hospital that closed last year after its sale fell through has filed a federal antitrust class action against healthcare conglomerate CVS over its 340B contract pharmacy policies.

The same shuttered hospital has been challenging in state court its

Read More »

Feds Pass on Asking Full Appeals Court to Reconsider Adverse 340B Contract Pharmacy Ruling and Vacate Enforcement Letters to Three Manufacturers

Third Circuit Court
The federal government opted not to ask a federal appeals court to reconsider its opinion upholding three drug makers' restrictions on 340B pricing when their drugs are shipped to be dispensed by contract pharmacies.

The federal government yesterday decided not to ask all 14 judges on the U.S. Third Circuit Court of Appeals in Philadelphia to review a three-judge panel’s unanimous January opinion upholding AstraZeneca, Novo Nordisk, and Sanofi’s restrictions on 340B pricing when

Read More »

Lilly Asks Covered Entity to Promptly Repay “Duplicate 340B/Medicaid Discounts”

Lilly
Eli Lilly is conducting government approved 340B provider audits that for the first time look for certain Medicaid health plan duplicate discounts.

Drug manufacturer Eli Lilly asked a 340B covered entity last week to promptly repay it for “duplicate 340B/Medicaid discounts” and evaluate all Lilly prescriptions that it or its contract pharmacies dispensed for the last three years.

Consultants and attorneys with

Read More »

New Group 340B Truth Seeks Provider Consensus on Federal Legislation

340B Truth
A new group, 340B Truth, is seeking a covered entity consensus position on 340B reform to take to Congress for quick action.

About a dozen people who advise, help run, or work at 340B covered entities are launching a nonprofit group, 340B Truth, to try to hammer out a covered entity consensus position on 340B reform and urge Congress to pass it

Read More »

HHS OIG and HRSA Are Mum About 340B Manufacturer Civil Monetary Penalties and Violation Notices

screenshot of HRSA correspondence to stakeholders web page
HRSA and OIG have no comment on the status of drug manufacturer civil monetary penalties and violation letters stemming from denials of 340B pricing to covered entities that use contract pharmacies.

The U.S. Department of Health and Human Services Office of Inspector General said yesterday it has no comment on the status of referrals from the U.S. Health Resources and Services Administration to fine eight drug manufacturers for failing to offer

Read More »

Calif. Contract Pharmacy Overbilled Medicaid for 340B Drugs, State Appeals Court Holds

PharmBlue specialty pharmacy wordmark
A California state appeals court affirmed a lower ruling that 340B contract pharmacy PharmBlue overbilled the state for 340B drugs it obtained from manufacturers on its clients' behalf.

A California state appeals court has affirmed a lower state court’s judgement that a 340B contract pharmacy overcharged the state Medicaid agency, Medi-Cal, nearly $2.5 million more than the pharmacy was entitled to receive for 340B drugs between May 2015

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live